908 Devices Inc. (MASS) stock intrinsic value fair value estimate & owner earnings analysis

908 Devices makes handheld chemical-identification instruments (including portable FTIR analyzers from its April 2024 RedWave acquisition) sold to government and industrial end users, plus precision optical components from KAF, acquired in July 2025. In March 2025 it sold its Desktop Portfolio (lab and pharma bioprocess instruments), which is why 2025 net income was a positive $19.5 million: a one-time $55.9 million gain on that sale, not a sign that operations became profitable. Revenue from the continuing business grew from $47.7 million in 2024 to $56.2 million in 2025, led by U.S. state and local authorities ($24.2 million) and overseas national and provincial organizations ($14.4 million); U.S. federal and defense fell from $16.8 million to $14.5 million. How we measure it: we take operating cash flow, strip out working-capital swings, subtract stock-based compensation as a real cost, and subtract maintenance capital spending. On that basis the company has produced negative owner earnings in every year we can measure: about -$0.72 per share in 2021, -$1.07 in 2022, -$1.09 in 2023, -$1.15 in 2024 and -$0.52 in 2025. The 2025 improvement is real but it is a smaller loss, not a profit. Roughly $9.8 million of 2025 stock compensation and $4.5 million of depreciation and amortization sit in these figures; the $40.7 million 2024 goodwill write-down and the $13.7 million 2025 increase in the fair value of acquisition earn-out obligations are non-cash and do not distort the cash-based measure. Because the 2025 cash flow still includes the Desktop business for part of the year, and about $4.4 million of costs tied to the sale, the 2025 figure is a mixed picture of the old and new company. Cases: we credit value only for earnings that are contracted or already demonstrated. The business has no year of positive owner earnings, so there is nothing yet to discount, and all three cases come out at $0 per share. Bear: the losses continue at the recent pace with no path to break-even. Base: the same, since revenue growth has not so far translated into cash profit after stock compensation. Bull: growth continues, but we did not credit margin expansion or scale benefits because none has been demonstrated. Some evidenced items were considered and found too small to change this: a June 2025 supply agreement with a large instrument maker commits $6.6 million of orders over three years (with a minimum $2.6 million cancellation fee), and the earn-out liability rose $13.7 million in 2025 because the company's own projections for FTIR revenue rose. Neither shows profitability. What we did not count: at December 31, 2025 the company held $70.5 million of cash and $42.5 million of U.S. Treasury securities, and it has a $16.0 million current earn-out liability. Our method values the earning power of the operations and does not add balance-sheet cash, so this cash cushion, which is what funds the current losses, is not in the $0. A reader who wants to value the cash should treat it separately and remember the business is consuming it. The shares could be worth more than our figure if the company reaches sustained cash profitability, which is what would need to happen before a margin-of-safety price could be set. What would make this wrong: if the newly acquired FTIR and precision-optics businesses scale to positive cash earnings after stock compensation, or if management cuts costs faster than revenue grows. We could not reconcile a clean continuing-operations-only cash flow from the filings, since the cash flow statement combines continuing and discontinued operations.